Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

POC Study in Partially Responsive Generalized Anxiety Disorder

ClinicalTrials.gov ID: NCT02310568

Public ClinicalTrials.gov record NCT02310568. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 1:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study aims to evaluate whether PF-06372865 is safe and effective in the treatment of sub-optimally controlled symptoms of generalized anxiety disorder during two 4-week treatment periods using a Sequential Parallel Comparison Design (SPCD). The study will use the Hamilton Anxiety Rating Scale (HAM-A) to measure change in symptoms from baseline for two doses of PF-06372865 compared to placebo.

Study identification

NCT ID
NCT02310568
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
90 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2014 (Type not available)
Primary completion
Oct 2015 (Actual)
Completion
Oct 2015 (Actual)
Last update posted
Jan 9, 2017

2014 – 2015

United States locations

U.S. sites
47
U.S. states
18
U.S. cities
44
Facility City State ZIP Site status
Comprehensive Clinical Development, Inc. Cerritos California 90703 —
Pharmacology Research Institute Encino California 91316 —
Sun Valley Research Center Imperial California 92251 —
Excell Research, Inc. Oceanside California 92056 —
NRC Research Institute Orange California 92868 —
California Neuorpsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC) San Diego California 92102 —
Artemis Institute for Clinical Research San Diego California 92103 —
Pacific Clinical Research Medical Group Upland California 91786 —
Hartford Hospital Hartford Connecticut 06102 —
Institute of Living Hartford Connecticut 06106 —
Avail Clinical Research, LLC DeLand Florida 32720 —
Gulfcoast Clinical Center Fort Meyers Florida 33912 —
Sarkis Clinical Trials Gainesville Florida 32607 —
Berma Research Group Hialeah Florida 33016 —
Clinical Neuroscience Solutions, Inc. Jacksonville Florida 32256 —
Sarkis Clinical Trials Lake City Florida 32025 —
Medical Research Group of Central Florida Orange City Florida 32763 —
Clinical Neuroscience Solutions, Inc. Orlando Florida 32801 —
Stedman Clinical Trials Tampa Florida 33613 —
Institute for Advanced Medical Research Alpharetta Georgia 30005 —
Atlanta Center for Medical Research Atlanta Georgia 30331 —
Northwest Behavioral Research Center Roswell Georgia 30076 —
Great Lakes Clinical Trials Chicago Illinois 60640 —
Phoenix Medica Research, Inc Prairie Village Kansas 66206 —
Pharmasite Research Inc Baltimore Maryland 21208 —
Beacon Clinical Research, LLC Brockton Massachusetts 02301 —
ActivMed Practices & Research, Inc Methuen Massachusetts 01844 —
BCCR Trials Natick Massachusetts 07160 —
Premier Psychiatric Research Institute. LLC. Lincoln Nebraska 68526 —
Center for Emotional Fitness Cherry Hill New Jersey 08002 —
Bio Behavioral Health Toms River New Jersey 08755 —
SPRI Clinical Trials LLC Brooklyn New York 11235 —
Neurobehavioral Research, Inc. Cedarhurst New York 11516 —
Comprehensive Clinical Development, Inc. Jamaica New York 11432 —
Bioscience Research LLC Mount Kisco New York 10549 —
Fieve Clinical Research, Inc New York New York 10168 —
Patient Priority Clinical Sites, LLC Cincinnati Ohio 45215 —
CTI Clinical Research Center Cincinnati Ohio 45227 —
Cutting Edge Research Group Oklahoma City Oklahoma 73116 —
Summit Research Network (Oregon) Inc. Portland Oregon 97210 —
Suburban Research Associates Media Pennsylvania 19063 —
Clinical Neuroscience Solutions, Inc. Memphis Tennessee 38119 —
Futuresearch Trials of Dallas Dallas Texas 75231 —
InSite Clinical Research, LLC DeSoto Texas 75115 —
Family Psychiatry of The Woodlands The Woodlands Texas 77381 —
Northwest Clinical Research Center Bellevue Washington 98007 —
Summit Research Network (Seattle) LLC Seattle Washington 98104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02310568, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 9, 2017 · Synced Sep 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02310568 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →